There have been various studies conducted so far in order to calculate the effects of statins in reducing cardiovascular events and slowing the progression of coronary atherosclerosis, the significant cardiovascular risk remains. icosapent ethyl, a highly purified acid, plays a very pivotal role in controlling the infections of the person in the best possible manner. The EVAPORATE trial sought to determine whether IPE 4g/ day, as an adjunct to diet and statin therapy, would result in a greater change from baseline in plaque volume. This has to be measured with the help of multidetector tomography. Therefore, for the purpose of this study, a total of 80 patients were taken so far. These people were the ones who were already infected by the diseases in the best possible manner. The results concluded that the icosapent ethyl demonstrated significant regression of LAP volume on MDCT compared with the placebo over the 18 months and was able to yield positive results in the best possible manner. Hence, an attempt must be made to cure these patients by using the best of genome sequencing in a better and reliable manner.

Ref link: https://www.thelancet.com/journals/langas/article/PIIS2468-1253(20)30057-1/fulltext